A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT03234972 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Velcade
DRUG: Dexamethasone

Sponsor

Janssen Research & Development, LLC